STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Verastem, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Verastem, Inc. (VSTM) filed an 8-K stating it reported financial results for the quarter ended September 30, 2025. The company furnished its earnings release as Exhibit 99.1 and posted an updated corporate presentation as Exhibit 99.2, both dated November 4, 2025.

This 8-K is an administrative disclosure that directs readers to the attached exhibits for details on operating performance and business updates. Verastem’s common stock trades on The Nasdaq Capital Market under the symbol VSTM.

Positive
  • None.
Negative
  • None.
false 0001526119 0001526119 2025-11-04 2025-11-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 4, 2025

 

Verastem, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-35403   27-3269467
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

117 Kendrick Street, Suite 500, Needham, MA   02494
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 292-4200

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange on which registered
Common stock, $0.0001 par value per share   VSTM   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 4, 2025, Verastem, Inc. (the “Company”) reported financial results for the quarter ended September 30, 2025, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. 

 

Item 7.01 Regulation FD Disclosure

 

On November 4, 2025, the Company posted its updated corporate presentation on its website, a copy of which is furnished hereto as Exhibit 99.2 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit No.   Description
99.1   Earnings Release, dated November 4, 2025
99.2   Corporate Presentation, dated November 4, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document) 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VERASTEM, INC.
     
Dated: November 4, 2025 By: /s/ Daniel W. Paterson
    Daniel W. Paterson
    Chief Executive Officer

 

 

 

FAQ

What did Verastem (VSTM) announce in this 8-K?

Verastem reported financial results for the quarter ended September 30, 2025, furnished as Exhibit 99.1, and posted an updated corporate presentation as Exhibit 99.2.

Which exhibits accompany Verastem’s 8-K filing?

The filing includes Exhibit 99.1 (Earnings Release), Exhibit 99.2 (Corporate Presentation), and Exhibit 104 (Cover Page Inline XBRL data).

Which 8-K items are referenced by Verastem (VSTM)?

Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).

When were the exhibits dated?

Both the earnings release and corporate presentation are dated November 4, 2025.

Where is Verastem’s stock listed and what is its ticker?

Verastem’s common stock trades on The Nasdaq Capital Market under the ticker VSTM.

Who signed the 8-K for Verastem?

The filing was signed by Daniel W. Paterson, Chief Executive Officer.
Verastem

NASDAQ:VSTM

VSTM Rankings

VSTM Latest News

VSTM Latest SEC Filings

VSTM Stock Data

581.60M
57.91M
0.82%
89.08%
25.94%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEEDHAM